ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Pneumococcal Conjugate Vaccine

Also written as “Multivalent”, “Pneumococcal Conjugate Vaccine (V114)” and “Pneumococcal conjugate vaccine”.

Its studies are mostly in Pneumococcal Infections, led by 4 companies.

Drug pagePneumococcal Conjugate Vaccine: every studyAll 12 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Apr 11, 20185 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer20 open or runningphase 2since Apr 11, 2018Apr 11, 2018none ahead
LG Chemits history only10 open or runningphase 1since Sep 2, 2016Sep 2, 2016none ahead
Merckits history only10 open or runningphase 2since Dec 27, 2011Dec 27, 2011none ahead
Sanofiits history only10 open or runningphase 1since Nov 18, 2024Nov 18, 2024none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Pfizer only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 11, 2018First study: phase 2 study in Pneumococcal InfectionsFirst studyNCT03512288 · 460 enrolled · United States
  2. May 25, 2018Phase 2 study in Pneumococcal InfectionsNCT03550313 · 565 enrolled · United States

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“An active immunizing vaccine used to prevent infection by the bacterium Streptococcus pneumoniae”NCIt, by rule
“Pneumococcal Conjugate Vaccine”name, by rule

Studies

All 2 Pfizer leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03550313Pneumococcal Infections · United States2TerminatedNov 5, 2020565
NCT03512288Pneumococcal Infections · United States2CompletedFeb 11, 2020460

How it is read

Names in the registry

  • “Multivalent”, 2 entries
  • “Pneumococcal Conjugate Vaccine”, 1 entry
  • “Pneumococcal Conjugate Vaccine (V114)”, 1 entry
  • “Pneumococcal conjugate vaccine”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.